Cytek Biosciences (CTKB) Other Accumulated Expenses (2020 - 2026)

Cytek Biosciences has reported Other Accumulated Expenses for 7 years, with the latest figure at $22.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 72.74% year-over-year to $22.2 million; the trailing twelve-month figure through Mar 2026 stood at $22.2 million (up 72.74% YoY), and the FY2025 full-year result was $17.0 million, up 25.82% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $22.2 million, up from $17.0 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $22.2 million in Q1 2026, with the low at $4.9 million in Q3 2022.
• Historically, Other Accumulated Expenses has averaged $10.8 million across 5 years, with a median of $8.4 million in 2023.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 316.73% — and 2024, when it dropped 24.24%.
• Cytek Biosciences' Other Accumulated Expenses stood at $8.0 million in 2022, then declined by 0.72% to $7.9 million in 2023, then surged by 70.75% to $13.5 million in 2024, then rose by 25.82% to $17.0 million in 2025, then surged by 30.6% to $22.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $22.2 million (Q1 2026), $17.0 million (Q4 2025), and $16.4 million (Q3 2025), per Business Quant data.